Oct 07

Jed Manocherian, Founder and Chairman of ACT for NIH: Advancing Cures Today, Statement on the Awarding of the 2020 Nobel Prize in Chemistry to Advisory Committee member Dr. Jennifer Doudna, UC Berkeley Professor of Molecular and Cell Biology and of Chemistry

We are thrilled that the Nobel Prize committee has chosen to honor ACT for NIH Advisory Committee member Dr. Jennifer Doudna with the Nobel Prize in Chemistry for her work on CRISPR-Cas9 and its almost limitless possibilities to change the way we prevent and cure diseases.

In 2012, using NIH funding, Dr. Doudna and her colleagues invented the CRISPR-Cas9 gene-editing technology, illustrating once again that NIH-funded research is a key driver of scientific discovery and innovation to improve human health in the United States and around the world. Congress can help ensure we see future groundbreaking research like CRISPR-Cas9 by maintaining the steady, robust funding increases for NIH it has enabled over the last five years. With this support, we will see further progress toward preventing and treating thousands of diseases and disorders for which there are no cures.

As a woman who is changing science as we know it, Dr. Doudna and her team at UC Berkeley are true pioneers in biomedical research and are most deserving of the 2020 Nobel Prize in Chemistry.

There are too many patients to be patient.